-
公开(公告)号:US09567391B2
公开(公告)日:2017-02-14
申请号:US14386228
申请日:2013-03-15
Applicant: Biogen Idec MA Inc.
Inventor: Kenneth Simon , Thomas Cameron , Mia Rushe , Justin Caravella , George Campbell Kaynor
IPC: A61K39/395 , C07K16/08 , A61K39/00
CPC classification number: C07K16/084 , A61K2039/505 , C07K2317/00 , C07K2317/24 , C07K2317/40 , C07K2317/76 , C07K2317/92
Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.
Abstract translation: 一方面,本公开提供了针对JCV的中和抗体和用于治疗PML的方法。 在一些实施方案中,本发明的方面涉及针对JCV衣壳蛋白VPI(JCV-VP1)的分离的JC-病毒中和单克隆抗体。 在一些实施方案中,抗体抑制JC-病毒的感染性。 在一些实施方案中,抗体结合JCV-VPI的唾液酸结合口袋。 在一些实施方案中,抗体结合包含一个或多个以下突变的JCV-VP1:S269F,S269Y,S267F,N265D,Q271H,D66H,K60E,K60N和L55F。
-
公开(公告)号:US20150050271A1
公开(公告)日:2015-02-19
申请号:US14386262
申请日:2013-03-15
Applicant: Biogen Idec MA Inc.
Inventor: Kenneth Simon , Thomas Cameron , Deping Wang , Joseph Arndt , Mia Rushe , Justin Caravella , Eric Day
IPC: C07K16/08
CPC classification number: C07K16/084 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.
Abstract translation: 一方面,本公开提供了针对JCV的中和抗体和用于治疗PML的方法。 在一些实施方案中,本发明的方面涉及针对JCV衣壳蛋白VPI(JCV-VP1)的分离的JC-vim中和单克隆抗体。 在一些实施方案中,抗体抑制JC-vims的感染性。 在一些实施方案中,抗体结合JCV-VP1的唾液酸结合口袋。
-
公开(公告)号:US20150056188A1
公开(公告)日:2015-02-26
申请号:US14386228
申请日:2013-03-15
Applicant: Biogen Idec MA Inc.
Inventor: Kenneth Simon , Thomas Cameron , Mia Rushe , Justin Caravella , George Campbell Kaynor
IPC: C07K16/08
CPC classification number: C07K16/084 , A61K2039/505 , C07K2317/00 , C07K2317/24 , C07K2317/40 , C07K2317/76 , C07K2317/92
Abstract: In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.
Abstract translation: 一方面,本公开提供了针对JCV的中和抗体和用于治疗PML的方法。 在一些实施方案中,本发明的方面涉及针对JCV衣壳蛋白VPI(JCV-VP1)的分离的JC-病毒中和单克隆抗体。 在一些实施方案中,抗体抑制JC-病毒的感染性。 在一些实施方案中,抗体结合JCV-VPI的唾液酸结合口袋。 在一些实施方案中,抗体结合包含一个或多个以下突变的JCV-VP1:S269F,S269Y,S267F,N265D,Q271H,D66H,K60E,K60N和L55F。
-
-